Iron chelator, prostate cancer conundrum on deck for ODAC
This article was originally published in Scrip
Executive Summary
The summer is over, and with a newly reorganized and renamed office under his reign, Dr Richard Pazdur, director of the US FDA's OHOP – the Office of Hematology and Oncology Products, and not, as some might assume, a moniker for the "Orderly House of Pazdur" – is ready to get back to work, seeking to cram as much into the agency's 14 September advisory committee hearing as possible, which the cancer drug chief has tended to do at recent meetings.